Business Wire

First Patient Recruited for Multi-Year Collaborative Primary Sclerosing Cholangitis (PSC) Pediatric Study Using Perspectum’s Imaging Technology to Help Predict Disease ...

SAN FRANCISCO--(BUSINESS WIRE)--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective ...
Science Daily

Largest ever genetic study of primary sclerosing cholangitis reveals potential drug target

Primary Sclerosing Cholangitis (PSC) is a debilitating rare disease of the liver with no effective treatment. Researchers have now identified four regions of the genome associated with the disease, ...
Financial Post

PSC Partners Announces the First Patient Enrolled Into the WIND-PSC Study, a Global Prospective Cohort to Support the Development of New Treatments for Primary Sclerosing ...

DENVER & TORONTO — PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the ...
Nasdaq

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic ...
Seeking Alpha

CymaBay And Seladelpar In PSC: The Imminent Phase 2 Study

Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions. PSC is caused by dysregulation of bile homeostasis ...